Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy
复制标题
DOI：
10.1093/eurjhf/hfq120
复制
发表时间：
2010-08-01
影响因子：
18.2
通讯作者：
McMurray, John J. V.
中科院分区：
文献类型：
--
作者：
Sliwa, Karen;Hilfiker-Kleiner, Denise;McMurray, John J. V.
围产期心肌病（PPCM）是妊娠心衰的一个原因。它通常发生在没有已知心血管疾病的妇女怀孕的最后一个月和怀孕后最多6个月。目前的立场声明提供了关于PPCM潜在病理生理机制、临床表现、诊断和管理的已知危险因素的最新总结。诊断需要高怀疑指数15，因为呼吸短促和脚踝肿胀在围产期很常见。围产期心肌病是一种独特形式的心肌病，与高发病率和死亡率相关，但也有完全恢复的可能性。氧化应激和催乳素心脏毒性亚片段的产生可能在PPCM的病理生理中起关键作用。在这方面，药物阻断催乳素提供了疾病特异性治疗的可能性。
Peripartum cardiomyopathy (PPCM) is a cause of pregnancy-associated heart failure. It typically develops during the last month of, and up to 6 months after, pregnancy in women without known cardiovascular disease. The present position statement offers a state-of-the-art summary of what is known about risk factors for potential pathophysiological mechanisms, clinical presentation of, and diagnosis and management of PPCM. A high index of suspicion 15 required for the diagnosis, as shortness of breath and ankle swelling are common in the peripartum period. Peripartum cardiomyopathy is a distinct form of cardiomyopathy, associated with a high morbidity and mortality, but also with the possibility of full recovery. Oxidative stress and the generation of a cardiotoxic subfragment of prolactin may play key roles in the pathophysiology of PPCM. In this regard pharmacological blockade of prolactin offers the possibility of a disease-specific therapy.